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Abstract 1 
 2 
In this work we have constructed two novel expression vectors, designated as pURI2 and 3 
pURI3, which enable parallel cloning of a given target gene for producing recombinant 4 
His-fusion proteins. The vectors were created using the well-known pT7-7 and pIN-III-A3 5 
plasmids as their template. The same DNA fragment containing the His-tag, enterokinase 6 
cleavage site, and a NotI unique site, as well as keeping the HindIII unique restriction site, 7 
was introduced in both vectors. These vectors have been designed to avoid the enzyme 8 
restriction and ligation steps during the cloning. The unique NotI site was introduced to 9 
facilitate the selection of the adequate recombinant plasmid. Parallel cloning of the same 10 
PCR fragment can be carried out since both vectors shared the same leader sequence. The 11 
described strategy avoids tedious cloning efforts into different expression vectors and 12 
represent a highly efficient means of cloning. To validate our vectors, we have cloned one 13 
target gene in both vectors and used expression and purification techniques to obtain the 14 
recombinant target protein. We herein show that both vectors function effectively in all the 15 
required experimental steps–cloning, expression, purification and cleavage. 16 
 17 
 18 
19 
 3
Introduction 1 
 2 
The genomic and structural genomic communities have driven the development of 3 
high-throughput cloning, expression and purification technologies to a large extent. The 4 
engineering of plasmids and expression vectors is one of the major tasks in a molecular 5 
biology laboratory. Many sophisticated plasmid constructions cannot be easily and rapidly 6 
engineered in a routine way. For example, the necessary endonuclease restriction sites 7 
might not be available or could be unsuitable for the desired constructions. Thus, a 8 
restriction enzyme-free cloning strategy is highly desirable. Several attempts to develop 9 
DNA cloning methods without the use of restriction enzymes and independent of DNA 10 
ligation have already been described (1, 2) and have been made commercially available. 11 
Some protocols incorporate the ligation-independent cloning (LIC) of target genes. LIC 12 
possesses several advantages; it eliminates the use of restriction endonuclease digestion and 13 
ligation of PCR products, allowing any gene to be cloned into the vector regardless of its 14 
sequence. In LIC, PCR primers are designed to append sequences that, after treatment with 15 
T4 DNA polymerase in the presence of a single deoxyribonucleotide triphosphate, generate 16 
12 to 15-base pair overhangs that are complementary to overhangs generated in the vector. 17 
These overhangs anneal sufficiently strongly to allow the transformation of hosts without 18 
ligation of the fragments; host repair enzymes ligate the introduced plasmid. In addition, 19 
another LIC method allows the insertion of PCR fragments in between any two nucleotides 20 
within a target plasmid. The only requirement is that the amplified fragment must be 21 
embedded between DNA sequences homologous to the site in which the integration is 22 
planned (3). 23 
 4
The purification of expressed proteins is accelerated by attachment of affinity tags 1 
to the N- or C-terminus of expressed proteins. They can provide hundred or even thousand-2 
fold purification from crude extracts without prior steps to remove nucleic acid or other 3 
cellular material. The mild elution conditions employed make affinity tags useful for 4 
purifying individual proteins and specially protein complexes. There are several 5 
commercially available affinity tags, such as the peptide hexahistidine, glutathione S-6 
transferase, maltose-binding protein,  covalent yet dissociable, FLAT, etc. among others 7 
(4). Tagging with hexahistidine residues has several merits: low levels of toxicity and 8 
immunogenicity, small size, and no electric charge (5). Usually, His-tag provides good 9 
yields of tagged protein from inexpensive, and high capacity nickel-chelating resins (4, 6). 10 
As these affinity tags may influence the tertiary structure of recombinant proteins 11 
and may interfere with protein function, removal of this tag seems advantageous and 12 
consequently a specific protease cleavage site need to be introduced in the vector. The 13 
enterokinase is a highly specific protease that cleaves a five-amino-acid recognition 14 
sequence. An enterokinase (EK) site allows removal of the affinity tag only, and does not 15 
leave any extra residues after cleavage on the target protein as compared to the native 16 
protein. 17 
As many of the commercially-available vectors encoding affinity tags require 18 
different cloning and purification step for each vector, we have developed two E. coli 19 
expression vectors for enzyme restriction- and ligation-independent cloning that allow for 20 
parallel cloning from a single PCR product and thus, the recombinant protein can then be 21 
purified by using the same protocol. 22 
 23 
 5
Materials and Methods 1 
 2 
 Strains. Escherichia coli DH5αF´ [F´/end A1 hsdR17 (rk-mk+) supE44 thi-1 recA1 3 
gyrA(Nalr) relA1 ∆(lacIZYA-argF)U169 deoR (φ80dlac∆(lacZ)M15; Promega] was used 4 
for all DNA manipulations and for expression in pURI2 vector. E. coli JM109 (DE3) 5 
[endA1 recA1 gyrA96 hsdR17 supE44 relA1 thi∆ (lac-pro) F´ (traD36 proAB+ lacIq 6 
lacZ∆M15) λcI857 ind1 Sam/ nin5 lacUV5-T7 gene 1; Promega] was used for expression 7 
in pURI3 vector. Lactobacillus hilgardii CECT 4786T (ATCC 8290) was purchased from 8 
the Spanish Type Culture Collection (CECT). Lactobacillus brevis RM273 was isolated 9 
from wine (7). Plasmids pIN-III(lppp-5)A3 (8, 9) and pT7-7 (USB) are expression vectors 10 
that allow the hyperexpression of the desired protein upon induction with isopropyl-β-D-11 
thiogalactopyranoside (IPTG).  12 
 L. brevis and L. hilgardii strains were routinely grown in MRS medium (10) at 30 13 
ºC without shaking. E. coli strains were cultured in Luria-Bertani (LB) medium (11) at 37 14 
ºC and 200 rpm. When required, ampicillin or chloramphenicol were added to the medium 15 
at a concentration of 100 or 34 µg ml-1, respectively. Chromosomal DNA, plasmid 16 
purification, and transformation of E. coli were carried out as described elsewhere (12). 17 
 18 
Construction of pURI2 and pURI3 vectors. The pUIR2 vector has been 19 
constructed starting from plasmid pIN-III(lppp-5)A3 (8, 9). First we performed a PCR using 20 
L. brevis RM273 DNA as template. We amplified a 230 bp from a non-coding intergenic 21 
DNA region (unpublished results). To perform the PCR we used two long synthetic 22 
primers, primers 246 and 245. The forward primer 246, from 5´to 3´ direction, contained: 23 
 6
22 nucleotides that paired the pIN-III(lppp-5)A3 sequence from the unique XbaI recognition 1 
site, a six poli-His tag, the enterokinase recognition site, and, 35 nucleotides pairing the L. 2 
brevis non-coding sequence (246, 5´-3 
ACTCTAGAGGGTATTAATAATGGGGGGTTCTCATCATCATCATCATCATGGTGAC4 
GATGACGATAAGATGCCTGCTACTGCTAATCGCTATCATTTTGGCGG) (the XbaI 5 
recognition site is underlined, the enterokinase recognition site is written in bold, and the 6 
poli-His tag in italics). 7 
The reverse primer 245 contains from 3´to 5´ direction, a HindIII restriction site, several 8 
stop codons arranged in tandem, a NotI restriction site, and 27 nucleotides pairing the L. 9 
brevis sequence (245, 5´- 10 
GGATCCAAGCTTAGTTAGCTATTATGCGTAGCGGCCGCAGATTCAGTAAAGCCT11 
CGTGTCGCTCG) (the HindIII and NotI restriction sites are underlined). The purified PCR 12 
fragment was digested with XbaI and HindIII, whose target sequences were incorporated 13 
into the primers, and cloned into pIN-III(lppp-5)A3 digested with the same restriction 14 
enzymes. The resulting plasmid of 7785 bp, pURI2 (Figure 1), encodes expression of a 15 
leader sequence consisting of a N-terminal methionine followed by three spacer amino 16 
acids, a six-histidine affinity tag, a spacer glycine residue, and the five-amino acid 17 
enterokinase recognition site, DDDDK, followed by an initial protein methionine, under the 18 
control of the lppp-5 and lacPO promoters, which can be induced at high levels by IPTG. 19 
The sequence and the site of insertion were verified by restriction analysis and DNA 20 
sequencing. 21 
Expression vector pURI3 was constructed based on the commercial expression 22 
vector pT7-7 (USB) (13) following the same strategy described above. We used L. brevis 23 
DNA as DNA template in the PCR reaction with long primers 244 and 245. Primer 244 was 24 
 7
identical to primer 246, except for that the nucleotides based on pIN-III(lppp-5)A3 1 
sequence were substituted by nucleotides based on the pT7-7 sequence containing a NdeI 2 
restriction site (244, 5´-3 
AGATATACATATGGGGGGTTCTCATCATCATCATCATCATGGTGACGATGACGA4 
TAAGATGCCTGCTACTGCTAATCGCTATCATTTTGGCGG) (the NdeI restriction site 5 
is underlined, the enterokinase recognition site is written in bold, and the poli-His tag in 6 
italics). As reverse primer we used primer 245. The purified PCR fragment was digested 7 
with NdeI and HindIII, and cloned into pT7-7 digested with the same enzymes. The 8 
resulting plasmid of 2690 bp, pURI3 (Figure 2) contained the same expression leader 9 
sequence found in pURI2 under the control of the T7 RNA polymerase φ promoter, which 10 
can be induced at high levels by IPTG. The pURI3 sequence was verified by restriction 11 
analysis and DNA sequencing. The pURI3 expression plasmid was amplified in the E. coli 12 
DH5α strain and then transferred, for protein production, to the host JM109(DE3) (pLysS) 13 
E. coli strain. These cells contain λDE3 as a permanent lysogen and the T7 RNA 14 
polymerase under the control of the lacUV5 promoter inducible by IPTG.  15 
 16 
Cloning, expression and purification of the target protein. To clone into the 17 
pURI2 and pURI3 expression vectors, the ornithine transcarbamoylase (OTC) gene 18 
sequence from L. hilgardii was amplified by Pfu DNA polymerase using the following 19 
oligonucleotides, forward 282 (5´- 20 
CATCATGGTGACGATGACGATAAGatgacaaaagattttagacaaaacg) and reverse 283 (5´-21 
AAGCTTAGTTAGCTATTATGCGTActaggaatgaataggttacccaaag) (the nucleotides pairing 22 
the expression vector sequence are indicated in italics, and the nucleotides pairing the OTC 23 
 8
gene sequence are written in lowercase letters). The amplification was for 20 cycles with 1 
the following conditions: 95 ºC 30 s, 55 ºC 1 min, 72 ºC for 3 min. After amplification, the 2 
PCR product was gel purified. This 1-kb purified PCR product was inserted into pURI2 and 3 
pUIR3 by using the restriction enzyme- and ligation-free cloning strategy described by 4 
Geiser et al. (2001) (3). Briefly, the purified PCR product was used as homologous primer 5 
pair in a PCR reaction using pURI2 or pUIR3 vectors as template. The product of this PCR 6 
was digested with DpnI that exclusively restricts methylated DNA, and later, with NotI, an 7 
enzyme that only cuts the original copies of pURI2 or pURI3 vectors. DpnI digestion was 8 
made directly in the PCR reaction buffer, and NotI digestion was made in buffer H (Roche). 9 
E. coli cells were transformed directly with the digestion product (Figure 3). 10 
The pURI2 expression plasmid was amplified in the E. coli strain DH5α and pURI3 11 
in the host JM109(DE3) (pLysS) E. coli strain. Cells carrying the recombinant plasmid 12 
were grown at 37 ºC in Luria-Bertani media containing ampicillin (100 µg/ml final 13 
concentration) and chloramphenicol (34 µg/ml final concentration) when required, and 14 
induced by adding IPTG (0.4 mM final concentration). After induction, the cells were 15 
grown at 22 ºC during 20 h and collected by centrifugation. Crude extracts were prepared 16 
by French Press lysis (three cycles at 1100 p.s.i.) of cell suspensions obtained by 17 
suspending the frozen cell paste with 20 mM Tris-HCl, pH 8.0, 100 mM NaCl. The 18 
insoluble fraction of the lysate was removed by centrifugation at 47 800 g for 30 min at 4 19 
ºC.  20 
 The cell homogenate, obtained by French Press lysis of the E. coli cells, was then 21 
applied to a His-TrapTM-FF crude chelating affinity column (Amersham Biosciences, 22 
Uppsala, Sweden) using an ÄKTA-Prime system (Amersham Pharmacia Biotech). The 23 
column was equilibrated with 20 mM Tris-HCl, pH 8.0, 100 mM NaCl containing 10 mM 24 
 9
imidazole, to improve the interaction specificity in the affinity chromatography step. The 1 
bound enzyme was eluted by applying a continuous gradient of imidazole concentration, 2 
from 20 mM Tris-HCl, pH 8.0, 100 mM NaCl containing 10 mM imidazole to 20 mM Tris-3 
HCl, pH 8.0, 100 mM NaCl containing 500 mM imidazole. Fractions containing the eluted 4 
OTC were pooled and the protein was then dialyzed against 20 mM Tris-HCl, pH 8.0, 100 5 
mM NaCl. The concentration of OTC was estimated using the Bio-Rad protein assay. 6 
Protein at a concentration of 2.5 µg/ml was incubated with one unit of recombinant 7 
enterokinase (Novagen) and allowed to incubate at 21 ºC for 4 or 8 hours. The sample was 8 
then run on a SDS gel to check the cleavage. 9 
 OTC activity was determined by measuring the formation of citrulline from 10 
ornithine and carbamyl phosphate according to a method described previously (14). 11 
  12 
Results and Discussion 13 
 14 
Characterization of pURI2 and pURI3 expression vectors. The emerging field of 15 
structural genomics embraces many diverse objectives, but in general depends on the 16 
generation of protein structural information at fast rate. To achieve this objective, every 17 
step involved in protein production must be efficiently optimised, including the cloning and 18 
expression of the target gene, and further purification steps of the target protein. The 19 
importance of these aspects is revealed by the fact that there are numerous commercially- 20 
and non-commercially available E. coli expression vectors that incorporate different 21 
backbones, promoters, tag positions and cloning procedures. As the final yield of protein 22 
production is dependent on the vector used, we set out to create two novel expression 23 
 10
vectors with the same cloning procedure and identical initial purification setup. The vectors 1 
pIN-III(lppp-5)A3 and pT7-7 were used as the basis for the new expression vectors. 2 
Expression vector pIN-III(lppp-5)A3 was chosen since it contains the promoter of 3 
the gene for the major outer membrane lipoprotein (lpp) that is considered to be one of the 4 
most efficient promoters in E. coli (9). In the high expression cloning pIN-III(lppp-5)A3 5 
vector, a lac promoter-operator fragment was inserted downstream of the lpp promoter 6 
(Figure 1). Therefore, transcription of a cloned gene in pIN-III(lppp-5)A3 occurs in the 7 
presence of lac inducers since this is regulated not only by the strong lpp promoter but also 8 
by the lac promoter-operator. 9 
Similarly, pT7-7 was selected since it contains the inducible bacteriophage T7 RNA 10 
polymerase promoter that provides the basis for a very active and selective gene expression 11 
system in E. coli (15). A convenient configuration has the gene for T7 RNA polymerase in 12 
the chromosome with the target gene in a multicopy plasmid under the control of a T7 13 
promoter. However, this configuration can be used only if the target gene is not too toxic, 14 
because basal level of T7 RNA polymerase activity in the uninduced state provides 15 
significant transcription of the target gene. Bacteriophage T7 lysozyme is a specific 16 
inhibitor of T7 RNA polymerase, and it can be used to lower the basal activity of T7 RNA 17 
polymerase in the T7 gene expression systems. Low levels of T7 lysozyme supplied by 18 
plasmid pLysS, which is compatible with the vector for expressing genes from a T7 19 
promoter, are sufficient to stabilize many target plasmids and yet allow high levels of target 20 
protein to be produced upon induction of T7 RNA polymerase (16). 21 
To improve these traditional expression vectors, we included a N-terminal His-tag 22 
that allows convenient purification of the protein from crude cell extracts (4), and also an 23 
enterokinase cleavage site that leaves no extra residues after cleavage on the target protein 24 
 11
as compared to the native protein. In order to establish a cloning protocol for both modified 1 
vectors, we decided to make use of the strategy described by Geiser et al. (2001) (3), an 2 
adaptation of the QuickChangeTM Site-Directed Mutagenesis protocol (Stratagene). This is 3 
a method that allows the insertion of PCR fragments in between any two nucleotides within 4 
a target plasmid. As the authors successfully integrated PCR fragments up to 1117 pb, we 5 
decided to included in the modified pIN-III(lppp-5)A3 and pT7-7 vectors a 230 bp sequence 6 
in order to facilitate the integration of larger DNA fragments. This 230 bp sequence was 7 
chosen from a L. brevis non-coding intergenic region (unpublished results), although any 8 
other non-coding piece of DNA could be also chosen. To construct the improved vectors 9 
we used long oligonucleotides pairing the L. brevis sequence and that contained all the 10 
required elements (poli-His tag, enterokinase recognition site, etc.) as described in Material 11 
and Methods section. Therefore, by using primers 246 and 245 we construct expression 12 
vector pURI2 (Figure 1) based on pIN-III(lppp-5)A3, and by using primers 244 and 245 we 13 
construct expression vector pURI3 (Figure 2) based on pT7-7 vector. Both expression 14 
vectors shared a common 310 bp fragment from the ATG start codon upstream the poli-His 15 
tag coding sequence to the HindIII restriction site (Figure 1 and 2). This common DNA 16 
fragment encodes for: a leader sequence consisting of a N-terminal methionine followed by 17 
three spacer amino acids, a six-histidine affinity tag, a spacer glycine residue, and the five-18 
amino acid enterokinase recognition site, DDDDK, followed by an initial protein 19 
methionine, the 230 pb non-coding intergenic L. brevis sequence, a rare-cut NotI restriction 20 
site, and four stop codons arranged in tandem, and, finally a HindIII restriction site (Figure 21 
1 and 2).  22 
   23 
 12
Cloning, expression, and purification of recombinant OTC protein. Figure 3 1 
shows the general procedure for parallel cloning into pURI2 and pURI3 vectors. To clone 2 
into the pURI2 and pURI3 expression vectors, PCR products of the gene of interest need to 3 
be generated with specific overhangs that are complementary to the integration site 4 
sequence of the vectors. Since both vectors shared common sequence, the PCR 5 
oligonucleotides primers could be designed in order to be used with both expression 6 
vectors. As a general rule, to clone any target protein into both vectors the sequence of the 7 
forward primer should be 5´- CATCATGGTGACGATGACGATAAGATG (the last three 8 
nucleotides encode the first methionine residue of the target protein) followed by 9 
nucleotides pairing the sequence from the second amino acid residue of the target protein 10 
(Figure 3). Similarly, the reverse primer, also common for both expression vectors, could 11 
be the sequence 5´-AAGCTTAGTTAGCTATTAAGCGTA followed by nucleotides 12 
pairing the sequence up to the stop codon of the target protein (Figure 3). The nucleotide 13 
sequence of the gene encoding the target protein is amplify by PCR using these 14 
oligonucleotides and Pfu DNA polymerase. After the reaction, the fragment is added to the 15 
methylated recipient template plasmid. After the denaturation step, the homologous parts of 16 
the PCR fragment hybridise to the defined integration site. The fragments are elongated in 17 
vitro by the Pfu DNA polymerase. The elongated and modified strands are not methylated. 18 
This cycle is repeated 30 times. Through cycling, copies of the unmethylated DNA 19 
embedding the PCR fragment are produced. DpnI is an enzyme that exclusively restricts 20 
methylated DNA. An additional screening tool is a NotI digestion of the template plasmid, 21 
only if a NotI restriction site is not included in the target gene sequence. However, this 22 
method is suitable for cloning any gene, even genes with internal NotI restriction sites. The 23 
DpnI and NotI digested PCR product can be transformed directly into E. coli and recovered 24 
 13
(Figure 3). Because each individual step of this procedure can be done in parallel, including 1 
the PCR, DpnI/NotI digestions, and the transformation, the protocol is suitable for parallel 2 
pURI2/pURI3 recombinant plasmid constructions. 3 
The utilization of pURI2 and pURI3 expression vectors was assessed by expressing 4 
the ornithine transcarbamoylase (OTC) gene sequence from L. hilgardii. Primers 282 and 5 
283 were designed to amplify the target OTC gene and append the appropriate sequences to 6 
the ends of the PCR products to allow its introduction into pURI2/pURI3 by the enzyme-7 
restriction and ligation-independent cloning strategy explained above. Each of the 8 
constructs was transformed into E. coli DH5α. The cloning efficiency of each vector, 9 
defined as the percentage of colonies that possessed the target protein, was evaluated. 10 
Efficiencies of 75 and 90% were obtained for pURI2 and pURI3 vectors, respectively. It 11 
should be mentioned, that long time digestion with DpnI (4 h) and NotI (2 h) were required 12 
to reduce sufficiently the background of colonies bearing pURI2 or pURI3 vectors. Success 13 
lies mainly in the degree of degradation, and secondarily in the linearization of the original 14 
vector, and therefore, the NotI restriction site was included in the designed expression 15 
vector. In addition, cloning efficiencies decreased according to the increase in the size of 16 
the gene encoding DNA fragment. Gene sequences up to 3 kb were successfully introduced 17 
into pURI2/pURI3 vectors (data not shown).   18 
E. coli DH5α and JM109 (DE3) strains were used for the cloning and expression of 19 
genes in pURI2 and pURI3 vectors. Expression vector pURI2 can be used in a single strain 20 
of E. coli in all steps from plasmid construction to the expression of the target gene. To 21 
express the target gene in the recombinant pURI3 plasmids, although it was initially cloned 22 
into E. coli DH5α strain, it need to be transformed into DE3 cells. In these cells, the T7 23 
polymerase gene is under the control of the IPTG-inducible lacUV5 promoter. Therefore, 24 
 14
the recombinant plasmid pURI3-OTC was transformed in E. coli JM109(DE3) (pLysS). 1 
OTC protein was expressed by IPTG induction, and following expression, the cultures were 2 
lysed, and centrifuged to sediment insoluble cell debris. As expected for vector based on T7 3 
polymerase, pURI3 generate very strong overexpression of cloned genes (15, 17) (Figure 4 
4B). Therefore, a significant OTC synthesis was observed in pURI3-OTC cell cultures after 5 
induction with 1 mM IPTG (Figure 4B). Otherwise, pURI2-OTC cell extract did not 6 
showed an apparent protein of the expected size, 38.3 kDa (Figure 4A). Even not obvious 7 
protein hyperproduction was achieved, the supernatant of sonicated cell lysates prepared 8 
from E. coli DH5α harbouring the recombinant plasmid pURI2-OTC showed OTC activity, 9 
whereas extracts prepared from control cells containing the vector plasmid alone did not 10 
(data not shown). Optimisation of soluble yields was not performed in this study, as this 11 
can vary greatly from protein to protein. 12 
Purification trials demonstrated that the His-tag and the EK cleavage site function 13 
properly. The functionality of the His-tag and the EK cleavage site of pURI2 and pURI3 14 
vectors was demonstrated by purifying OTC protein. OTC was purified on a His-TrapTM-15 
FF crude chelating affinity column and eluted with a continuous gradient of imidazole. 16 
Highly purified OTC protein was obtained from both expression vectors (Figure 4). In 17 
pURI2-OTC (Figure 4A) in spite of that soluble OTC protein showed a very faint band in 18 
the soluble fraction, it could be purified at detectable quantity (Figure 4A, line 3). 19 
Generally, affinity tags are removed after purification as they can interfere with 20 
either the protein function or with downstream processes. Each construct above described 21 
has an EK cleavage site which can be used to remove the affinity tag, leaving the native 22 
protein. To validate the EK cleavage site, the purified OTC protein was dialyzed and 23 
 15
digested with EK. As showed in Figure 5 commercial EK (Novagen) cleaved the target 1 
protein efficiently, as half of the purified OTC was cleaved in 8 h at 21 ºC. 2 
 3 
Conclusion 4 
In summary, the results presented herein showed that the developed pURI2 and 5 
pURI3 expression vectors allow the overexpression and further purification of native 6 
proteins. Because of the variability of biological samples, no one vector is ideal for all 7 
proteins. In this sense, the expression vectors developed here present the advantage that the 8 
same PCR product can be introduced into both expression vectors following the same 9 
strategy. Additionally, this strategy allows the introduction of a 1 kb DNA fragment having 10 
at each side only short regions of homology covering the insertion point. We also have 11 
successfully introduced PCR fragments up to 3 kb into pURI2/pURI3 vectors by using this 12 
strategy. A N-terminal His-tag allows convenient purification of the native protein directly 13 
from crude cell extracts. The His-tag can be cleaved off from the purified protein by 14 
utilizing an enterokinase cleavage site that yield the native protein. The described strategy 15 
allows parallel cloning of any gene, avoiding tedious cloning efforts into different 16 
expression vectors. 17 
 18 
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Figure captions 2 
 3 
Figure 1. (A) Schematic representation of the expression vector pURI2 (7785 bp). (B) 4 
Sequence of pURI2 containing the leader sequence encoding region. The expression leader 5 
sequence consists of a N-terminal methionine residue followed by a three-amino acid 6 
spacer, a six-histidine affinity tag, a spacer glycine residue, and the five-amino acid 7 
enterokinase recognition site, DDDDK, followed by an initial protein methionine. The 8 
expression leader sequence is under the control of the lppP-5 and lacPO promoters. Cleavage 9 
of expressed proteins by EK occurs between the lysine and methionine residues (KM). 10 
Restriction sites are indicated and underlined in the nucleotide sequence. Tandem stop 11 
codons are indicated by asterisks. 12 
 13 
Figure 2. (A) Schematic representation of the expression vector pURI3 (2690 bp). (B) 14 
Sequence of pURI3 containing the leader sequence encoding region. The expression leader 15 
sequence consists of a N-terminal methionine residue followed by three-amino acid spacer, 16 
a six-histidine affinity tag, a spacer glycine residue, and the five-amino acid enterokinase 17 
recognition site, DDDDK, followed by an initial protein methionine. The expression leader 18 
sequence is under the control of the T7 polymerase φ promoter. Cleavage of expressed 19 
proteins by EK occurs between the lysine and methionine residues (KM). Restriction sites 20 
are indicated and underlined in the nucleotide sequence. Tandem stop codons are indicated 21 
by asterisks. 22 
 23 
 19
Figure 3. General procedure for ligation-independent cloning into pURI2 and pURI3 1 
expression vectors. The primer sequences homologous to pURI2/pURI3 vectors are 2 
indicated. The HindIII restriction site on the reverse primer is underlined. The stop codons 3 
are indicated by asterisk.  4 
 5 
Figure 4. Expression and purification of the 38.3 kDa OTC protein from L. hilgardii 6 
cloned into pURI2 and pURI3 vectors. SDS-PAGE analysis of soluble cells extracts of 7 
IPTG-induced cultures. (A) Expression on pURI2. Lane 1, E. coli DH5α (pURI2); lane 2, 8 
E. coli DH5α (pURI2-OTC); lane 3, L. hilgardii OTC from E. coli DH5α (pURI2-OTC) 9 
eluated after His-TrapTM-FF crude chelating affinity column. (B) Expression on pURI3. 10 
Lane 1, E. coli JM109 (DE3) (pLysS) (pURI3); lane 2, E. coli JM109 (DE3) (pLysS) 11 
(pURI3-OTC); lane 3, L. hilgardii OTC from E. coli JM109 (DE3) (pURI3-OTC) eluated 12 
after His-TrapTM-FF crude chelating affinity column. The 12% (A) and 10% (B) 13 
polyacrylamide gels were stained with Coomassie blue. The positions of molecular mass 14 
markers (Bio-Rad) are indicated on the left.  15 
 16 
Figure 5. Cleavage of  L. hilgardii OTC protein by enterokinase. OTC was purified on His-17 
TrapTM-FF crude chelating affinity column, eluted with buffer containing 125 mM 18 
imidazole, dialyzed overnight into 20 mM Tris-HCl, pH 8.0 buffer free of imidazole, and 19 
treated with enterokinase at 21 ºC. Lane 1, untreated; lane 2, 4 h incubation; lane 3, 8 h 20 
incubation. Broad-range molecular weight markers (Bio-Rad) are run on the left, and some 21 
positions are indicated. 22 
23 
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A 4 
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 11 
 12 
B 13 
 14 
  SspI        lpp promoter 15 
AATATTGACAACATAAAAAACTTTGTGTTATACTTGTAACGCTACATGGAGATTAACTCAATCTAGCTAG 16 
      -35                     -10 17 
 18 
                               lac promoter-operator 19 
AGAGGCTTTACACTTTATGCTTCCGGCTCGTATAATGTGTGGAATTGTGAGCGGATAACAATTTCACACA 20 
  -35                     -10 21 
 22 
                                      XbaI RBS 23 
GGAAACAGCTATGACCATGATTACGGATTCACTGGAACTCTAGAGGGTATTAATAATGGGGGGTTCTCAT 24 
                                                        M  G  G  S  H 25 
 26 
     His tag     EK recognition site 27 
CATCATCATCATCATGGTGACGATGACGATAAGATGCCTGCTACTGCTAATCGCTATCATTTTGGCGGGA 28 
 H  H  H  H  H  G  D  D  D  D  K  M 29 
 30 
 31 
CACCTGGCATCAGCCCCGCTAACCCTGCGGCCCAAAATCGGGTATACTGAACCTAACTCTTAGTAGAAAG 32 
 33 
 34 
TAGGTCAGCGTCATTGGCAAATTACATCAAGGAAATTCGCGAACTCGTCGGTCACAAACCCATCATTCTT 35 
 36 
                                                       NotI 37 
AACGCTTCTGGTGGTCTGGTGACCAACGAGCGACACGAGGCTTTACTGAATCTGCGGCCGCTACGCATAA 38 
                                                          *  39 
 40 
        HindIII  BamHI 41 
TAGCTAACTAAGCTTGGATCCGGCTGAGCAACGACGTGAACGCAA 42 
 *   *   *                                                    43 
lppP-5 lacPO ATG ATGHis EK
X N H B
LacI      ApR
pURI2
(7.8 kb)
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A 6 
 7 
 8 
 9 
 10 
 11 
 12 
 13 
 14 
 15 
 16 
 17 
 18 
 19 
 20 
 21 
 22 
 23 
 24 
 25 
B 26 
 27 
                      T7 promoter 28 
GATAGACTTCGAAATTAATACGACTCACTATAGGGAGACCACAACGGTTTCCCTCTAGAAATAATTTTGT 29 
 30 
 31 
            RBS        NdeI               His Tag       EK recognition 32 
TTAACTTTAAGAAGGAGATATACATATGGGGGGTTCTCATCATCATCATCATCATGGTGACGATGACGAT 33 
                          M  G  G  S  H  H  H  H  H  H  G  D  D  D  D   34 
 35 
site 36 
AAGATGCCTGCTACTGCTAATCGCTATCATTTTGGCGGGACACCTGGCATCAGCCCCGCTAACCCTGCGG 37 
 K  M 38 
 39 
 40 
CCCAAAATCGGGTATACTGAACCTAACTCTTAGTAGAAAGTAGGTCAGCGTCATTGGCAAATTACATCAA 41 
 42 
 43 
GGAAATTCGCGAACTCGTCGGTCACAAACCCATCATTCTTAACGCTTCTGGTGGTCTGGTGACCAACGAG 44 
 45 
                         NotI                   HindIII  ClaI 46 
CGACACGAGGCTTTACTGAATCTGCGGCCGCTACGCATAATAGCTAACTAAGCTTATCGATGATAAGCTG 47 
                                      *  *   *   * 48 
 49 
 50 
TCAAACATGAGAATT 51 
 52 
 53 
54 
Ø10 ATG ATGHis EK
Nd N H
ApR
pURI3
(2.7 kb)
C
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Figure 3 1 
2 
AMPLIFICATION OF THE TARGET GENE 
    H  H  G  D  D  D  D  K  M       
5´-CATCATGGTGACGATGACGATAAGATG-----------------------------------3´ 
                            protein 
3´--------------------------------(Stop)ATCGCTTAATAGCTAACTAAGCTT–5´ 
                                               *  *   *   * 
CLONING INTO pURI2/pURI3 VECTORS 
1. PCR using: 
•Pfu DNA polymerase 
•pURI2/pURI3 as template plasmid 
•PCR amplified target gene as primer 
2. DpnI and NotI digestion 
3. Transformation into E. coli 
 23
Figure 4 1 
 2 
3 
 24
Figure 5 1 
 2 
 3 
